Evogene (EVGN)
AI-guided small-molecule discovery for medicines and crop protection.
Something off on this page? Send us feedback.
Develops AI-designed small molecules for pharmaceutical and crop-protection programs, earning collaboration payments, potential milestones and royalties, while also selling castor seed varieties and support. The business is concentrated around ChemPass AI after divesting or reducing other computational-biology activities.
Uses ChemPass AI to design and optimize small molecules for drug discovery and crop protection. Its computational unit combines virtual screening, analogue search and generative design with laboratory and validation capabilities across curated chemical spaces. Pharmaceutical collaborations pair molecular design with partners' experimental, development and commercialization work.
AgPlenus applies the agricultural platform to novel herbicides and fungicides, while Casterra retains high-yield castor seed varieties, agronomic support and Brazil-focused operations. Revenue can arise from partner payments, research funding, milestones and royalties, alongside seed sales. Candidate progression depends on experimental validation, development partners, regulatory approvals, intellectual-property protection and access to external capital.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 26, 2026 | Industrial Alliance Securities | Target | Target: — | Target: $2.15 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.4M · Total debt $2.1M · Total assets $13.4M · Shareholders' equity −$3.3M
- Revenue
- $347.0K
- Operating income
- −$2.4M
- Net income
- −$1.8M
No dividends on record.
| Insiders | 0.01% | 1.1K ADS | |
|---|---|---|---|
| 1 holder · as of Aug 26, 2026 | |||
| Other | 99.99% | 8.72M ADS | |
| remainder | |||
8.72M ADS as of Sep 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Gabi TarcicInsiderofficer: Chief Development Officer | 0.01% | 1,129 ordinary | filed Aug 26, 2026 |
ARK Investment Management LLCInstitution | —6.01% of class, as filed | — | filed Feb 9, 2022 |
Alpha Capital AnstaltStrategic | —8.81% of class, as filed | — | filed Nov 2, 2020 |
Armistice Capital, LLCStrategic | —9.99% of class, as filed | — | filed May 15, 2026 |
Harel Insurance Investments & Financial Services Ltd.Strategic | —4.50% of class, as filed | — | filed Jan 29, 2019 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 4, 2026 | Gabi Tarcic | officer: Chief Development Officer | +1,129 | $0.6000 |
| Aug 11, 2026 | Leon Recanati | director | +460,000 | $0.6350 |
| Aug 4, 2026 | Leon Recanati | director | +800,000 | $0.5000 |
- Schrödinger
Physics-plus-AI design platform for small-molecule discovery.
- Recursion Pharmaceuticals
AI-native chemistry and biology platform for partnered drug programs.
- FMC
Global crop-protection innovator in herbicide and fungicide discovery.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Evogene | $0.4935 | +3.31% | $4.0M | — | — | 3.1 | −60.8% |
| Schrödinger | $31.00 | +0.98% | $2.26B | — | — | 8.7 | +7.5% |
| Recursion Pharmaceuticals | $4.04 | −0.25% | $2.08B | — | — | 38.0 | −61.8% |
| FMC | $10.57 | 0.00% | $1.29B | — | 7.5 | 0.4 | −17.5% |
| Median | — | 7.5 | 8.7 | −17.5% |